Literature DB >> 32366559

Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.

Janice S Ahn1, Ali Al-Habib2, Jeffrey A Vos1, Aliyah R Sohani3, Oralia Barboza-Quintana4, Juan P Flores4, Sijin Wen5, Flavia G Rosado6.   

Abstract

This study aims to characterize the tumor microenvironment of plasmablastic lymphoma (PBL) in regard to the quantities of CD163(+) tumor associated macrophages (TAM) and PD1(+) tumor infiltrating lymphocytes (TIL). This article also reviews the existing knowledge of the role of PD-1/PD-L1 pathway in the tumor microenvironment of hematopoietic neoplasms, discusses potential mechanisms to explain our findings, and outlines areas for future studies. We performed CD163 and PD1 immunohistochemical studies in 11 cases classified as plasmablastic lymphoma, and recorded the percentages of positive TAMs and TILs. Based on previous studies, cut off values of ≥30% and >5% were used to classify the cases into high TAMs and TILs, respectively. We determined that the majority of cases (8 of 11, or 73%) had high percentage of TAMs, while only a minority had high percentage of TILs (3 of 11, or 27%). Our data shows a trend towards a negative correlation between TAMs and TILs (p=0.08), and a predominance of the pattern TAMhigh/TILlow (7 of 11, or 63%) compared to other patterns. The microenvironment of plasma-blastic lymphoma tends to show high percentage of TAMs (≥30%) combined with low percentage of TILs (≤5%). Additional studies are needed to determine the clinical significance of TILs and the influence of EBV and HIV infections on numbers of TILs in PBL. As high microenvironment TAMs have been associated with high microenvironment PD-L1 in other hematopoietic malignancies, our data supports the need for future studies on the expression of PD-L1 in PBL.
© 2020 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  CD163; PD-1; plasmablastic lymphoma; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 32366559      PMCID: PMC7439522     

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  22 in total

Review 1.  Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.

Authors:  Stephen M Ansell
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

2.  Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.

Authors:  Sari Riihijärvi; Idun Fiskvik; Minna Taskinen; Heli Vajavaara; Maria Tikkala; Olav Yri; Marja-Liisa Karjalainen-Lindsberg; Jan Delabie; Erlend Smeland; Harald Holte; Sirpa Leppä
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

3.  Tumor-associated macrophages in diffuse large B-cell lymphoma.

Authors:  Robert Kridel; Christian Steidl; Randy D Gascoyne
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

4.  Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma.

Authors:  Matthew J Ahearne; Kaljit Bhuller; Roger Hew; Hazem Ibrahim; Kikkeri Naresh; Simon D Wagner
Journal:  Virchows Arch       Date:  2014-07-11       Impact factor: 4.064

5.  Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage.

Authors:  TuDung T Nguyen; Erich J Schwartz; Robert B West; Roger A Warnke; Daniel A Arber; Yasodha Natkunam
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

6.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

7.  Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.

Authors:  Colm Keane; Frank Vari; Mark Hertzberg; Kim-Anh Lê Cao; Michael R Green; Erica Han; John F Seymour; Rodney J Hicks; Devinder Gill; Pauline Crooks; Clare Gould; Kimberley Jones; Lyn R Griffiths; Dipti Talaulikar; Sanjiv Jain; Josh Tobin; Maher K Gandhi
Journal:  Lancet Haematol       Date:  2015-10-01       Impact factor: 18.959

8.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

9.  Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.

Authors:  Simone Muenst; Sylvia Hoeller; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

10.  CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma.

Authors:  Jonathan A Harris; Salvia Jain; Qinghu Ren; Alirezah Zarineh; Cynthia Liu; Sherif Ibrahim
Journal:  Diagn Pathol       Date:  2012-01-30       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.